TERT promotor variant associated with poor clinical outcome in a patient with novel RBM15‐MKL1 fusion‐positive pediatric acute megakaryoblastic leukemia
- 2 August 2020
- journal article
- letter
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (1), e28542
- https://doi.org/10.1002/pbc.28542
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortiumBlood, 2018
- Primary Budd‐Chiari Syndrome in ChildrenJournal of Pediatric Gastroenterology and Nutrition, 2017
- Pediatric non–Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomesNature Genetics, 2017
- Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup studyBlood, 2016
- Understanding TERT Promoter Mutations: A Common Path to ImmortalityMolecular Cancer Research, 2016
- Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international studyBlood, 2015
- The biology of pediatric acute megakaryoblastic leukemiaBlood, 2015
- Myeloproliferative Neoplasms and Recurrent Thrombotic Events in Patients Undergoing Liver Transplantation for Budd-Chiari Syndrome: A Single-Center ExperienceAnnals of Transplantation, 2014
- Nineteen cases of the t(1;22)(p13;q13) acute megakaryblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study groupLeukemia, 2000
- The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group StudyBlood, 1991